BWVI — Psycheceutical Bioscience Balance Sheet
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.06m
- -$0.88m
Annual balance sheet for Psycheceutical Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2009 December 31st | 2010 December 31st | 2011 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | PROSPECTUS | PROSPECTUS |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.511 | 0.209 | 0.866 | 0.327 | 1.99 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.257 | 0.79 | 0.387 | 0 | 0 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.935 | 1.01 | 1.26 | 0.327 | 2.09 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.07 | 0.043 | 0.029 | — | — |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 2.33 | 1.72 | 1.8 | 0.327 | 2.37 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.11 | 1.1 | 1.48 | 0.264 | 2.42 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Liabilities | 1.75 | 1.1 | 1.48 | 0.264 | 2.42 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 0.576 | 0.62 | 0.322 | 0.063 | -0.045 |
Total Liabilities & Shareholders' Equity | 2.33 | 1.72 | 1.8 | 0.327 | 2.37 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |